29.08.2012 - A pioneering genetics research centre at the University of Edinburgh receives £60m (€75,6m) funding from the Medical Research Council (MRC).
The university has also received a £3.5m (€4,4m) award from the Wellcome Trust and Wolfson Foundation to help fund the building of a new systems medicine centre. The MRC funding will be used to fund research at Edinburgh's MRC Human Genetics Unit and the MRC Institute of Genetics and Medicine (IGMM) into a range of conditions, such as schizophrenia, cystic fibrosis, and genetic eye disorders, and to develop and test new therapies. IGMM is a partnership between the MRC, the University of Edinburgh's Centre for Molecular Medicine, and Cancer Research UK.
“This funding will help us to turn the potential of the genetic revolution into reality” said Institute director Nick Hastie in a video. He explained that most of the money would continue to fund ongoing programmes in the Human Genetics Unit, but that “ten to twenty percent, combined with money from the University of Edinburgh, will allow us to do exciting new science”. This would include recruiting top researchers, purchasing new equipment, developing a brand new PhD programme and helping the centre to integrate its research with the NHS. Professor Hastie said that the ‘big aim’ was to bring the results of research into clinical practice to aid the diagnosis and treatment of disease.
The £3.5m in funding from the Wellcome Trust and the Wolfson Foundation, awarded under the Wellcome-Wolfson Capital Awards programme, will support a new systems medicine building with the construction set to start in 2013 at Edinburgh's Western General Hospital. The five-story systems medicine building will total 2,700 meters squared, and will "create a physical and intellectual bridge between centres that make up the IGMM. In addition to research spaces, the facility will include spaces for computational biology, a seminar room, offices, and an "open design" to encourage research collaborations, according to IGMM. The remainder of the estimated £10.2m for the systems medicine facility will be provided by the University of Edinburgh and the MRC.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more